Kepley BioSystems Announces New Role to Support Upcoming Product Launch

Lee Robertson and Auri, his 2-year old Siberian Husky.

Lee Robertson and Auri, his 2-year old Siberian Husky.

Robertson and Auri on the Gateway Research Park North Campus

Robertson and Auri on the Gateway Research Park North Campus

Kepley BioSystems Logo

The KBI Logo

Kepley BioSystems assigns Lee Robertson position of Director of Scientific Communications and Operations

It was a very challenging and demanding program and Lee was not only able to succeed, but thrive in this environment. We are very lucky to have him.”

— Dr. Christopher Kepley

GREENSBORO, NC, USA, April 24, 2019 / — Kepley BioSystems Incorporated (KBI) has established the position of Director of Scientific Communications and Operations in preparation for the release of a novel entry into the companion animal sector. This new role represents an exciting assignment for Lee Robertson, who has assisted in KBI product research and development in emerging technologies while applying his design and multi-media talents to develop the corporate image and website. His skills will be pivotal for introducing a new product based on Kepley molecular research into olfactory behavioral drivers for various species.

“We are all excited that Lee took on these new responsibilities in advance of our upcoming launch,” Anthony Dellinger, president of KBI said and continued, “He brings a wealth of experience, marketing savvy and creativity to this new role.”

Robertson has worked as a research scientist/technician since starting with Chris Kepley at the Joint School of Nanoscience and Nanoengineering (JSNN) in 2014. He has built on dual degrees in applied nanoscience technology and the humanities, as well as becoming certified in design software, resulting in exceptional scientific communications abilities. His organizational, commercial operations, IT and sales experience also evolved earlier in his career with Walmart and Sam’s Club, spanning nearly 16 years of electronics sales, inventory management and supervisory roles. Ultimately, Robertson led his team to be one of the top 50 performing Technology Departments in the company (out of more than 550 Sam’s Club stores).

Earning sales awards in three consecutive years – combined with his entrepreneurship on behalf of design clients of his off-hours graphic arts studio – no doubt enhanced the marketing expertise that Robertson looks forward to applying to support the first commercialized product for Kepley BioSystems. In this new position, Robertson will: take the lead as the primary media contact; continue to shape the corporate identity and online presence; and direct an array of operations processes, as the start-up continues to develop its team.

Kepley, KBI founder and a JSNN professor, looked back to welcoming Robertson to the world of nanoscience, "It was a very challenging and demanding program and Lee was not only able to succeed, but thrive in this environment. We are very lucky to have him."

# # #

About Kepley BioSystems:
Kepley BioSystems (KBI) is a North Carolina-based life sciences start-up operating out of Gateway Research Park (GRP) in collaboration with the Joint School of Nanoscience and Nanoengineering (JSNN), comprised of a partnership between the North Carolina Agriculture and Technical State University (NCA&T) and the University of North Carolina at Greensboro (UNCG). KBI was founded in 2013 with a mission to emerge disruptive innovations to achieve global solutions. For more information, visit:

Anthony Dellinger
Kepley BioSystems Incorporated
+1 336-217-5163
email us here
Visit us on social media:

Source: EIN Presswire

Onera Health raised $9.3M+ in Series A funding to revolutionize sleep diagnostics

Onera Health Logo

Onera Health Management Team

This funding is a key step towards bringing the healthcare startup closer to realizing its mission.

PALO ALTO, CA, USA, April 24, 2019 / — Onera Health Inc., a leader in sleep diagnostic solutions and services, announced it raised $9.3M+ in Series A funding. Led by Jazz Pharmaceuticals, imec.xpand, as well as other investors including imec and BOM, this funding is a key step towards bringing the healthcare startup closer to realizing its mission – to revolutionize sleep diagnostics with the world’s first at-home medical grade sleep diagnostic patch system.

The need for better sleep testing is great. One in five people struggle to get through the day because a sleep disorder affects them at night. Whether it’s insomnia, sleep apnea, narcolepsy or a host of other disorders, people suffering with these conditions don’t often seek out a proper diagnosis. For many, the process of being tested at a sleep clinic is uncomfortable, inconvenient, intimidating and expensive, and even motivated patients often need to wait months for an appointment.

“We believe the solutions Onera Health are developing could transform diagnostic and treatment-monitoring processes in sleep medicine,” said Jed Black, M.D., Senior Vice President, Sleep and CNS Medicine at Jazz Pharmaceuticals and adjunct professor, Stanford University Medical Center, Stanford Center for Sleep Sciences and Medicine. “Onera’s hardware and software innovations, as well as its streamlined service model, have the potential to empower clinicians to provide patients with optimal sleep care.”

Headquartered in California’s Silicon Valley, with R&D offices in the Netherlands, Onera focuses on breakthrough sleep testing solutions that are quick, convenient and clinically accurate. Two simple patches will replace cumbersome sensors usually attached to the face, scalp, chest and limbs. Doctors will benefit from test results matching the accuracy of conventional in-lab sleep clinics while patients will rest easier being monitored at home or in a medical setting suggested by their doctor. Ultimately, patients and physicians alike will enjoy easier access to accurate sleep diagnostics at a fraction of the cost.

“Imec.xpand invests in companies that have the potential to become global players by disrupting their entire industry,” said Tom Vanhoutte, Partner at imec.expand and Board Member of Onera Health. “We’re convinced that the Onera team, and their close cooperation with imec, has the skills, business acumen and vision to set the new gold standard in sleep diagnostics.”

Onera answers to millions struggling to get a good night’s sleep, solving pressing issues for:

– Patients – The very people who need help are stymied by difficult-to-get appointments, cumbersome diagnostics and monitoring outside their natural sleep setting.
– Hospitals and Sleep Centers – Currently, sleep testing takes up too much space and staff time for setup and monitoring, valuable resources that could be used to treat other ailments; on top of that reimbursement and profits are low.
– Referring Physicians – Many doctors are unfamiliar with sleep disorders and have little time to understand and act on sleep study reports.
– Sleep Center Physicians – As medical directors and staff physicians, they’re overburdened by managing technicians, clinic logistics, frustrating pre-authorization requirements, and declining reimbursements. They need to rechannel their efforts toward patient care instead.

Onera’s goal is to resolve these pain-points through the development and use of its sleep diagnostics service model. As Onera’s Co-Founder & CEO, Raphael Michel says, “Our mission is to help the medical field provide the much-needed answers for millions who are affected by sleep disorders. For far too long, people avoided searching for those answers because understanding their issues was expensive, inconvenient or unreliable. And nobody enjoys spending hours hooked up to sensors in a sleep lab. Soon, thanks to our technology partnership with imec, our medical-grade, disposable patches will accurately diagnose sleep-related ailments in the comfort of a patient’s own bed and using it will be as simple as putting on a band-aid. We’re making sleep diagnosis accessible to many without compromising quality. And thanks to the investment from Jazz and others, we keep expanding the continuum of sleep care.”

“Imec is proud of the progress made by Onera. It’s inspiring to see another imec spin-off having great success in creating breakthrough medical technologies,“ stated Luc Van den hove, President and Chief Executive Officer at imec. “Onera is capitalizing on its new funding to revolutionize the field of sleep studies, adhering to imec's core focus of innovation in nanoelectronics and digital technologies.“ John Baekelmans, Managing Director and VP at imec in the Netherlands, is pleased to see Onera’s progress and is excited for its future with imec: “Eindhoven is a great incubator for successful startups, and Onera continues that tradition. Imec looks forward to continuing to support and collaborate with this ambitious entrepreneurial team.”

Over the next several months, Onera plans to launch pilot programs across the country to work with leaders in sleep medicine, including pulmonologists, neurologists and psychiatrists, ENTs, pediatricians, and the military. Hartmut Schneider M.D., Ph.D., Onera’s Co-Founder & Chief Medical Officer, and Associate Professor at Johns Hopkins University, explains: “Being a leader in sleep research, I’ve always strived to teach sleep specialists and primary care physicians alike, passing on the knowledge, skills and insights necessary to diagnose and treat sleep disorders. Onera’s innovations are like finding the missing piece to a puzzle; the medical field finally has the tools they need to offer comprehensive sleep care.”

Max de Leseleuc
Onera Health
+1 805-574-0845
email us here

Onera Health

Source: EIN Presswire

Immunitor запустил вторую фазу испытаний пероральной иммунотерапевтической вакцины для лечения рака головного мозга

мы используем версию аллогенной вакцины из пула раковых клеток, но в случае необходимости можем произвести индивидуальную аутологичную вакцину по заказу любого пациента всего за одну неделю”

— Aldar Bourinbaiar

Гонгконг, Гонгконг, April 24, 2019 / — Immunitor China Ltd. (Гонконг) заявила о начале испытания иммунотерапевтической вакцины V-Boost на пациентах с наиболее распространенной формой опухоли головного мозга – мультиформной глиобластомой (МГБ). Ожидается, что в открытое исследование фазы II (NCT03916757), в которое в настоящее время проводится набор, будут включены по меньшей мере 20 пациентов с впервые диагностированной или рецидивирующей глиобластомой с историей хирургического удаления опухоли.

Мультиформная глиобластома (МГБ) – это самая смертельная форма опухоли мозга, состоящая из дифференцированных опухолевых астроцитов – подтипа клеток образующих центральную нервную систему (ЦНС). Глиобластома клинически классифицируется как астроцитома IV степени и отличается от анапластической астроцитомы (III степень) наличием некротических тканей и гиперпластических кровеносных сосудов. В последние годы глиобластома стала более знакома публике благодаря широко разрекламированной связи данного заболевания с именами сенаторов Теда Кеннеди и Джона Маккейна, а также сына Джо Байдена Бо, скончавшихся от МГБ. По приблизительным оценкам, у 15000 человек в США ежегодно диагностируют глиобластому со средней выживаемостью от 12 до 15 месяцев. Из них менее 5% больных остаются в живых через пять лет. Почти каждый пациент с данным злокачественным заболеванием имеет крайне неудовлетворительные шансы на выживание, поскольку годовой показатель смертности от глиобластомы практически равен аналогичному показателю заболеваемости ею.

Поиск эффективного и в то же время нетоксичного средства для лечения опухоли головного мозга является непростой задачей. Применение одобренных управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США раковых препаратов, как то темозоломида, бевацизумаба, динутуксимаба, ломустина и кармустина, приводит лишь к незначительному повышению выживаемости без прогрессирования или общей выживаемости, но к очень малому проценту полной ремиссии. Десятки кандидатов лекарственных препаратов, изученных за последнее десятилетие, не смогли повысить выживаемость пациентов выше уровня стандартного медицинского лечения. Различные иммунотерапии и противораковые вакцины, испытанные за последние несколько лет, не принесли существенного прогресса, не смотря на что исследования упорно продолжаются в надежде найти исцеление.

V-Boost компании Immunitor – это вакцина против рака, способная сохранять стабильность при комнатной температуре и полученная из пула раковых клеток пациентов, циркулирующих у них в крови, и образцов их опухолевых тканей, которые подвергаются гидролизу и затем пакуются в запатентованные нами пероральные таблетки, которые следует принимать один раз в день. Опухолевые антигены доставляются через антиген-презентирующие клетки, выстилающие тонкий кишечник – самый большой иммунный орган в организме человека, который играет роль, подобную роли дендритных клеток. Предыдущие исследования показали, что иммунные клетки, сформированные под воздействием V-Boost, могут преодолевать гематоэнцефалический барьер и вызывать должный иммуный ответ, но без нежелательной воспалительной реакции. Считается, что V-Boost эффективнее вакцин на основе дендритных клеток, поскольку последние представляют собой лишь небольшую часть клеток, участвующих в иммунной регуляции.

В ходе исследования фазы II участники будут получать ежедневную дозу таблетки V-Boost в дополнение к стандартной терапии, которая может включать в себя хирургическое вмешательство, химиотерапию, облучение или ингибиторы контрольных точек иммунного ответа. Основная цель исследования – оценить влияние на динамику роста опухоли и проанализировать общую выживаемость или выживаемость без прогрессирования в качестве вторичных конечных точек исследования. «Реакция на наш препарат, которую мы наблюдаем у некоторых пациентов с заболеваниями головного мозга, очень обнадеживающая и не ограничиватеся только данным заболеванием. Рынок препаратов для лечения МГБ, который по прогнозам достигнет 1,15 миллиардов долларов США к 2024 году, составляет лишь малую долю глобального рынка терапии ЦНС, равному 128,9 миллиардов долларов», – говорит доктор Аллен Бэйн, директор Immunitor Inc. из Ванкувера. «Мы надеемся скоро получить результаты второй фазы испытаний, чтобы подтвердить наши предварительные выводы. Потенциал развития при положительном исходе исследования будет существенным, поскольку направлен на излечение рака мозга – категории заболевания, не имеющего каких-либо эффективных средств лечения», – заявляет д-р Алдар Буринбаяр, генеральный директор холдинга Immunitor. «Клинические исследования нашей вакцины V-Boost были начаты несколько лет назад. Учитывая превосходную безопасность и эффективность этого препарата для лечения пациентов с нейродегенеративными заболеваниями, наши усилия, направленные на получение его одобрения для лечения раковых опухолей, будут значительно упрощены. В настоящее время мы используем готовую версию аллогенной вакцины, производимую из пула клеток разных пациентов, но в то же время в случае необходимости можем произвести индивидуальную аутологичную вакцину по заказу любого отдельного пациента всего за одну неделю», – поясняет д-р Буринбаяр.

О компании Immunitor
Immunitor является биофармацевтической компанией, вышедшей на коммерческий уровень развития и зарегистрированной в Гонконге, с имеющимися дочерними компаниями в Пекине, Улан-Баторе, Москве, Йоханнесбурге и Ванкувере. Преимущество и лидирующая позиция компании Immunitor заключается в разработанной ею платформе доступных по цене пероральных вакцин, подтвержденных многочисленными клиническими испытаниями, проведенными за последние два десятилетия. Immunitor имеет в наличии 22 препарата для пероральной иммунотерапии, предназначенных для лечения заболеваний в основных областях здравохранения, т.е. инфекционных болезней, различных аутоиммунных и метаболических заболеваний, и с недавних пор – заболеваний в иммуно-онкологической сфере. Immunitor успешно запустил в производство вакцины против гепатоцеллюлярной карциномы, холангиокарциномы и рака поджелудочной железы. В прошлом году Immunitor начал пять клинических исследований фазы II у женщин с эндометриозом, миомой, раком шейки матки, яичников и молочной железы, которые активно ведутся в настоящее время. Компания так же проводит и другие исследования по иммунотерапии для иных клинических показаний.

Aldar Bourinbaiar
+1 301-476-0930
email us here

Source: EIN Presswire

The Mars Generation Announces 24 Under 24 Leaders and Innovators in STEAM and Space Award Winners for 2019

Naia Butler-Craig 2

Lee Giat

Carlla Martins

We know that, given the right tools and the right support, today’s youth can have a tremendous impact on changing the world both now and in the future.”

— Tory Bruno, CEO of United Launch Alliance

MINNEAPOLIS, MN, UNITED STATES, April 23, 2019 / — The Mars Generation (TMG) announced its second class of 24 Under 24 Leaders and Innovators in STEAM and Space Award winners. The group is comprised of young people from around the world who are breaking barriers in science, technology, engineering, arts, and math (STEAM) fields and bringing the sciences to the public through multidisciplinary interests. The youngest winner of this international recognition is 13 years old. To qualify for consideration nominees must be members of TMG’s Student Space Ambassador Leadership Program, be under the age of 24 and be involved in work or a project that is focused on STEAM.

“The 24 Under 24 awards elevate youth accomplishments in STEAM fields, empowering and encouraging them to continue working for a brighter future,” said Abigail Harrison, Founder, The Mars Generation. “This year’s 24 Under 24 are doing exceptional work in STEAM, and perhaps even more importantly, in bringing STEAM interest and education beyond their computers and labs, including to rural towns and underrepresented communities.”

Sponsored in 2019 by the United Launch Alliance, the winners for 24 Under 24 are involved in a variety of STEAM interests, including designing mobile apps for social causes, founding nonprofits for science education and inclusion, building open-source lead detection technology, 3D printing prosthetic limbs, developing multi-state star party programs, and facilitating in-class programs in areas of the world where science education has not previously been a priority.

The winners are not only active in academic communities, but also in helping to lift up underrepresented voices–inspiring young people to reach for their goals, improving accessibility in STEAM fields, and creating films or writing books about their discoveries. The 24 Under 24 embody the philosophy of “going above and beyond”–many of them founding their own organizations and/or mentoring young people.

“Working with the 24 Under 24 awards program to identify and catalyze the efforts of young people in STEAM is important to innovation and advancement of industries worldwide,” said Tory Bruno, CEO of United Launch Alliance and The Mars Generation Advisory Board Member. “We know that, given the right tools and the right support, today’s youth can have a tremendous impact on changing the world both now and in the future.”

“Like those youth honored in our inaugural 24 Under 24 class, this year’s winners are ambassadors of The Mars Generation mission to build a stronger tomorrow by energizing our youth today about space and STEAM no matter what it takes,” said Harrison. “STEAM changes the world, and so do people who not only innovate, but also share ideas with passion. That’s what 24 Under 24 is about, and how our 2019 class shines.”

The 2019 winners of the 24 Under 24 Leaders and Innovators in STEAM and Space are:
1. Laalitya Acharya
2. Payton Barnwell
3. Hunar Batra
4. Abigail Bollenbach
5. Simon Bouriat
6. Naia Butler-Craig
7. Aja Capel
8. Julia Di
9. Archika Dogra
10. Tiera Fletcher
11. Lee Giat
12. James Gong
13. Anagha Krishnan
14. Sara Lam
15. Casey Mann
16. Carlla Martins
17. Sophya Mirza
18. Avika Patel
19. Olivia Pierce
20. Gitanjali Rao
21. Jordan Reeves
22. Taylor Richardson
23. Roberto Rodrigues-Otero
24. Maria Gisllanny Bezerra Silva

About The Mars Generation
The Mars Generation is a volunteer-driven 501(c)(3) nonprofit with an advisory board that includes astronauts, engineers, scientists, and professionals from the nonprofit and business communities. Reaching millions of people since 2015, the organization has served students and adults from around the world through multiple programs, including the Student Space Ambassador Program, Future of Space Outreach Program, and Space Camp Scholarship Program. The Mars Generation is supported by private donors, members, influencer work, and major corporate sponsors. Through an innovative approach of leveraging new media technology and providing engaging content and programs, the organization aims to excite and educate students and adults about the importance of human space exploration and STEAM education to the future of humankind.

For more information on The Mars Generation, go to:

About United Launch Alliance
With more than a century of combined heritage, ULA is the world’s most experienced and reliable launch service provider. ULA has successfully delivered 133 satellites to orbit that provide Earth observation capabilities, enable global communications, unlock the mysteries of our solar system, and support life-saving technology.

Yvonne Hundshamer
The Mars Generation
+1 612-625-6366
email us here

Source: EIN Presswire

The Impact of Advancements in Biotechnology on the Treatment of Disease & Aging

Biotechnology report cover

A new PreScouter report investigates how new innovations and billions of dollars in research can improve the health and longevity of patients

While advances in biotechnology open up the treatment and even the cure of chronic disease, one of the current barriers facing biotechnology moving forward is purely logistical.”

— Dr. Vidhya Sivakumaran, PreScouter

CHICAGO, ILLINOIS, USA, April 23, 2019 / — PreScouter, a Chicago-based research intelligence company, has released a detailed report on the recent advances in biotechnology and how these advances are helping promote better treatments of disease and slow down the aging process. With the biotechnology sector expected to reach nearly 727 billion USD by 2025 and with the enormous number of advances in the field every month, PreScouter identifies in this report which innovations are particularly likely to have an impact in the next 5 to 10 years and what groups are powering these discoveries.

Dr. Vidhya Sivakumaran, the author of the report, notes that while advances in biotechnology open up the treatment and even the cure of chronic disease, “one of the current barriers facing biotechnology moving forward is purely logistical; a number of steps in the research process face logistical hurdles which have yet to be overcome by the development of novel processes.” By providing both a scientific and business perspective on the industry, this report highlights what these logistic barriers are and how they may be overcome by the cutting-edge research happening today.

The report first highlights advances in cell therapies and gene editing and their potential in slowing down the aging process and curing disease. The second part addresses the challenges faced in curing diseases and advancing health, exploring areas such as the microbiome, nano-scale therapies, and personalized medicine. The report includes an exclusive interview with Dr. Trevor Martin, CEO of Mammoth Biosciences, a biotechnology company specializing in developing CRISPR-based diagnostic tools. According to Dr. Martin, he sees “CRISPR systems becoming the platform for a wide variety of applications beyond gene editing over the next 5-10 years.”

“Biotechnology may lead to the creation of new tissue for transplantation, cell, and gene therapies which may lead to cures for chronic diseases and even a treatment for aging,” notes Dr. Sivakumaran. However, improvements in the underlying science are required to power these discoveries, adds Sivakumaran. PreScouter presents this report to serve as a robust primer, highlighting potentially disruptive advances in the field of biotechnology. The report comes as the first chapter of a series of “disruptors” reports PreScouter will be releasing successively.

About PreScouter, Inc.: PreScouter provides research support services to help business leaders make better R&D, product development, and corporate development decisions. PreScouter’s custom-selected teams of Advanced Degree Researchers and Industrial Experts connect business leaders with new markets, commercializable technologies, industry-impacting startups, and other actionable data. PreScouter’s growing list of 500+ clients includes GE Healthcare, Coca-Cola, BAE Systems, Clorox, and Volvo. For more info, please visit

Mariam Jomha
+1 872-222-9225
email us here

Source: EIN Presswire

Immunitor initiates Phase II trial of oral immunotherapy vaccine to treat glioblastoma brain cancer

We currently have off-the-shelf version of allogeneic vaccine, but at the same time we are capable of making individualized, autologous vaccine in as short as one-week time”

— Aldar Bourinbaiar

HONG KONG, HONG KONG, April 23, 2019 / — Immunitor China Ltd. (Hong Kong) announces launching immunotherapeutic V-Boost vaccine trial in patients with most common form of brain tumor – glioblastoma multiforme (GBM). The open-label Phase II trial (NCT03916757), which is now recruiting, is expected to enroll at least 20 patients with newly diagnosed or recurrent glioblastoma who may have undergone surgical removal of their tumor.

Glioblastoma multiforme (GBM) is a high-grade glioma and the deadliest astrocytic tumor, composed of variously differentiated neoplastic astrocytes – a subtype of brain cells forming the central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. In recent years, glioblastoma became more familiar to the public due to extensively-publicized association with names of senators Ted Kennedy and John McCain, and Joe Biden’s son Beau. The estimated 15,000 people in the USA are diagnosed with glioblastoma annually and have a median survival of 12 to 15 months; less than 5% are alive after five years. Almost every patient with this malignant cancer faces poor survival odds since yearly death rate is the same as the annual incidence.

Finding an effective, but at the same time non-toxic treatment, for brain tumors has been a major challenge. The FDA approved drugs temozolomide, bevacizumab, dinutuximab, lomustine and carmustine wafers have shown modest improvements in progression-free or overall survival, but insignificant percentage of complete remissions. The dozens of drug candidates evaluated in the past decade have failed to improve survival beyond the standard of care. Various immunotherapies and cancer vaccines tested in last few years made no meaningful progress, although research is underway with hope of finding cure.

Immunitor’s V-Boost is a stable-at-room-temperature cancer vaccine derived from a pool of patients’ own cancer cells circulating in their blood and samples of tumor tissues, which are hydrolyzed and formulated into proprietary oral tablet to be taken once-daily. Tumor antigens are delivered via antigen-presenting cells lining the gut – the largest immune organ in a human body that can play a role like that of dendritic cells. Prior studies have shown V-Boost educated immune cells can pass blood-brain barrier and found to be effective and free of harmful inflammation. It is believed that V-Boost performs better than vaccines based on dendritic cells as these represent only a minor fraction of cells involved in immune regulation.

Over the course of the Phase II trial, participants will receive daily pill of V-Boost in addition to standard of care, which may include surgery, chemotherapy, radiation, or checkpoint inhibitors. The trial’s main goal is to evaluate effect on tumor shrinking and assess overall or progression-free survival as secondary endpoints. “The response we see in some patients with brain disorders is very encouraging, it is not limited to GBM only, which equals to global market size USD 1.15 billion by 2024 – representing the tiny proportion of CNS therapeutics worth $128.9 billion”, says Dr Allen Bain, the Director of Vancouver-based Immunitor Inc. “We look forward to outcome of Phase II trial to confirm our preliminary findings. The potential will be substantial since brain cancers are in unmet need category”, said Dr. Aldar Bourinbaiar – CEO of Immunitor holding company. “Our V-Boost vaccine has been clinically validated starting some years ago; given familiarity with excellent safety and efficacy of this product in patients with neurodegenerative diseases it will facilitate our effort of seeking approval for tumor cancers. We currently have off-the-shelf version of allogeneic vaccine, but at the same time we are capable of making individualized, autologous vaccine in as short as one-week time”, added Dr. Bourinbaiar.

About Immunitor
Immunitor is a commercial stage biopharmaceutical company registered in Hong Kong with subsidiaries in Beijing, Ulaanbaatar, Moscow, Johannesburg, and Vancouver. Immunitor’s strength and leading position resides in its affordable oral vaccine’s platform validated by multiple clinical trials conducted over last two decades. Immunitor markets 22 oral immunotherapy products addressing major health problems, i.e., in infectious diseases area; a variety of autoimmune and metabolic diseases; and recently in immuno-oncology space. Immunitor has successfully launched advanced trials for hepatocellular carcinoma, cholangiocarcinoma, and pancreatic cancer. Last year, Immunitor started five Phase 2 trials in patients with endometriosis, uterine fibroids, cervical, ovarian, and breast cancer. These and additional immunotherapy studies for other indications are still ongoing.

Aldar Bourinbaiar
Immunitor Inc
+1 301-476-0930
email us here

Source: EIN Presswire

VAFFLE APP Releases News that Almost Half of the Hospitals in the UK will Permit Outdoor Vaping

Vaping Zone

VAFFLE APP Releases News that More UK Hospitals will Permit Outdoor Vaping

Quit Smoking

The hospitals have removed smoking shelters and replaced them with designated outdoor vaping points

Almost half of the hospitals in the UK reported a change in their vaping policies as guidance from PHE suggests vaping on hospital grounds should be lifted.

Cigarette smoking is still a major cause of ill health and death in the UK, related policies need to be updated according to the latest scientific evidence.”

— Vaffle

NEW YORK, UNITED STATES, April 23, 2019 / — Almost half of the hospitals in the UK reported a change in their policies towards vaping. This move is a result of the recommendation by Guidance from Public Health England (PHE). They suggested that vaping on hospital grounds should be lifted.

One of the most recent hospitals to follow these recommendations is NHS Tayside in Scotland. Vaping is now allowed on the grounds of the hospital. However, vapers should still avoid entrances, doorways and seating areas to make sure those surrounding are not exposed to nicotine vaper.

Tayside is the third Scottish hospital to allow the use of e-cigarettes on its grounds after NHS Scotland lifted the e-cig ban. Recently, a Nottingham hospital chose to allow the use of e-cigs their grounds, too.

“We are pleased to be able to update our smoking policy and take into account the latest scientific evidence,” said Andrew Radley, a consultant for the public health pharmacy.

“NHS Tayside is a health-promoting organization and encourages all of our patients, visitors and staff to observe our smoking policy and keep all of our premises and grounds smoke-free.”

Officials now want vaping allowed inside and outside of hospitals too.

The hospitals have removed smoking shelters and replaced them with designated outdoor vaping points. New signage has been installed across the sites, particularly in areas where smokers used to gather as well.

Officials went one step forward and now want vaping allowed inside and outside hospitals.

The Tobacco Control Plan continued with the statement that vaping products should also be sold in hospital shops. This plan even considers allowing vaping in hospital beds when the patient is in a single room.

The decision was made following widespread evidence that e-cigs help people reduce their intake, and are significantly less harmful than regular cigarettes. And besides that, according to the latest study published in the New England Journal of Medicine, cigarettes are almost twice as effective as nicotine-replacement therapy (NRT) to help individuals quit smoking when both are accompanied by behavioural support. It shows that switching to an e-cigarette could be one of the most effective ways to quit smoking.

However, ‘A Freedom of Information’ request has shown that over half of the hospitals in the UK have an outright ban on vaping. 170 NHS trusts responded, 55% of which explained that they banned vaping both indoors and outdoors. 89% of respondents banned vaping inside the hospital.

+86 137 9524 8180
email us here
Visit us on social media:

Source: EIN Presswire


Authentico Technologies

Swedish company changes the playing field for storing passwords and encryption keys.

Authentico Technologies (PC:Private company)

GOTHENBURG, SWEDEN, April 23, 2019 / — The Swedish based cybersecurity start-up Authentico Technologies, developed a centralized hardware unit that can be installed on an enterprise’s servers. The product, named CIPHRA, is a hardware device that makes password theft essentially impossible even if a database is stolen. Passwords and other sensitive data are protected because no secret key material are stored anywhere. The device works as a plug-and-play product and, once running, it enhances security without any change in the user experience or login process.

The technology called PUF (physically unclonable functions) is used by turning this slightly noisy fingerprint of the chip into a reliable root key. Whenever the root key is needed by the system, CIPHRA reliably reconstructs it without the need for storing this root key in any form of memory and They are virtually impossible to clone or predict.

When using PUF, cryptographic keys and identities are derived from a digital fingerprint in the start-up behavior of SRAM cells. This means the secret material is never stored in memory and no physical traces can be found on a chip that lead to the secret material. Hence, using SRAM PUF protects secrets from reverse engineering attacks, simply by virtue of the fact the secrets are not present on the chip in any physical form. So, besides removing the requirement for externally provisioning keys to chip (because they are created from the silicon imperfections internally), storing keys with PUF also provides a level of se¬curity that cannot be achieved with any other form of key storage, due to the fact that keys are not physically stored on the chip.

“Our approach, to generate strong unclonable keys and not store them anywhere, makes theft of passwords and encryption keys essentially impossible,” said Philip Lundin Weinstock, chief executive officer of Authentico Technologies. “The exposure of passwords has reached alarming levels, there are approximately 8 billion stolen passwords that are accessible via the dark web today and new data breaches are reported more or less each month now”.

We guarantee our customers that passwords, or the password hashes are useless to an attacker if they get stolen, regardless of the password strength and the resources available to the hacker. This is something that can not be guaranteed by recommended hashing algorithms since the time it takes to crack a password offline, depends on the strength of the password itself. Weaker passwords get cracked very fast using sophisticated dictionary lists and brute force attacks with dedicated hardware. Besides that these kind of attacks improves all the time, hardware is also getting cheaper and more powerful every single year.

The major problem with the current approaches is that they do not stop data from being stolen in the first place. Rather it might delay the use of the stolen data for an uncertain period of time that depends on both the computational resources available to the attacker and weaknesses being found in algorithms, along with findings published by researchers.
One of the key problems is that personally identifiable infor¬mation is stored using industry standard architecture which is vulnerable to various attacks. Encryption keys can usually be exploited inside code or maintained in files on servers and wherever they are stored. Hackers and insiders can in¬filtrate those hidden places which put the whole organiza¬tion at serious risk.

Philip says: “The problem we see is that the vast majority of users do not change their behavior – How many years have the community informed people about generating strong passwords, turn on two factor authentication and use a recommended password manager?
A tiny minority does that, but the majority does not. We must ask ourselves, what can we do to improve the security for the users, not what the users can do themselves”.

Philip Lundin Weinstock
Authentico Technologies
+46 73 322 10 40
email us here
Visit us on social media:

Source: EIN Presswire

Tissue Solutions Ltd wins Queen’s Award for Enterprise….Again

Tissue Solutions

Tissue Solutions Ltd, an award winning tissue acquisition company has won the prestigious Queen's Award for Enterprise in the International Trade category.

GLASGOW, UNITED KINGDOM, April 23, 2019 / — Tissue Solutions Ltd, an award winning virtual biobank and tissue acquisition company that helps researchers ethically source biological materials, has won the prestigious Queen's Award for Enterprise in the International Trade category. Now in its 53rd year, these awards are announced on the Queen’s birthday and are one of the UK’s highest accolades recognising business achievement. It is the second time Tissue Solutions has been recognised for its excellence in International Trade, having also collected the award in 2014.

Commanded by CEO Dr Morag McFarlane, the company has been supplying high quality human biomaterials and scientific expertise to multinational companies since 2007. It is now an established and reputable supplier of biospecimens, and the only UK-owned human tissue acquisition group. Sourcing through a global network, the company provides scientists with biomaterials for pre-clinical research across the drug development pipeline, from identification and validation, screening and testing, right through to pre-clinical trials. Samples can be anything from fresh tumour samples, used for work on Immuno-Oncology, to skin samples for use in toxicology and dermatological testing of products. They specialise in supplying samples to stringent specifications, offering exceptional turn-around times and taking care of the logistics of transporting biomaterials across geographical borders. Samples can also be collected on demand, through the companies volunteer donor database, where volunteers can sign up to donate samples to support research in areas close to their heart.

The award has been presented in recognition of Tissue Solutions’ outstanding business success within International Markets and achieved by continual investment in growth and innovation. In the last three years, Tissue Solutions has seen overseas growth of 216 per cent and over 80 per cent repeat order success by servicing global clients across Europe, USA, Australia and Asia. The business currently employs 20 staff and is based at the West of Scotland Science Park in Glasgow.

Dr Morag McFarlane CEO of Tissue Solutions said, “We are thrilled to receive the Queen’s Award again for Enterprise in the International Trade category. Our foundations were built on the development of a sample acquisition service, and we now also offer a comprehensive range of tissue related CRO services as standard, as well as a range of bespoke services”

Morag said: "The award is an acknowledgment of the effort put in by everyone at Tissue Solutions to ensure the best possible customer service to our clients, who have shown their appreciation by their custom and loyalty. Our philosophy is that the best research comes from the best samples, and we are proud to be supporting advancements in biomedical research"

For further information on Tissue Solutions visit
Tissue Solutions Ltd
+44 141 299 0055
email us here
Visit us on social media:

Source: EIN Presswire

Onchain Custodian, the crypto & digital asset custodian backed by Sequoia, announces its first customers & partnerships

Onchain Custodian clients and partners 23/04/2019

First batch of clients & partners

Onchain Custodian

Onchain Custodian Executives

Onchain Custodian, the digital asset custodian backed by Sequoia, Fosun & DHVC, announced today the on-boarding of its first customers & important partnerships.

SINGAPORE, April 23, 2019 / — Following its successful platform and service launch, Onchain Custodian (ONC), the digital asset custodian backed by Sequoia, Fosun and DHVC, announces today the on-boarding of its first customers as well as the establishment of important partnerships.

Headquartered in Singapore, Onchain Custodian has developed a personalized and comprehensive custody service for institutional players and accredited investors to secure digital assets with institutional grade security and controls. The SAFE™ Digital Asset Custody Platform is flexibly built to meet the possible futures of digital asset custody.

Onchain Custodian’s launch event took place at the Mandarin Oriental Singapore on the 11th of April during the Asia Pacific Blockchain New Finance Summit. The event attracted VIP guests from all over the world, from Canada to China. Some have announced at this occasion their plans to use Onchain Custodian’s services.

On top of the Ontology Foundation, which announced publicly two weeks ago its use of the service, Tembusu Partners, Pre Angel, JLAB | JD Capital, Fission Capital, Frees Fund, Timestamp Capital, Milestone, among seven others, will start the on-boarding process with Onchain Custodian in the coming weeks.

Mr. Pak Lum MOCK, Managing Partner at Tembusu Partners. “As a leading private equity firm with deep roots in Emerging Asia, Tembusu holds digital asset investments that we want to be safe and properly managed. We trust that Onchain Custodian, with its strong Asia Pacific footprint, will offer us the personalised service we are looking for.”

Mr Jian SUN, Founder of JLAB | JD Capital: “Onchain Custodian’s founders and backers are a strong testimonial of the seriousness of the project. By safekeeping our digital assets with ONC, we are following the best practice that should prevail for any institutional investments; independent third-party custody.”

Ms Sandy Peng, Partner of Fission Capital: “Digital asset investments are tricky to manage in view of the current diversity of blockchain and token protocols. Having the secure single window access to blockchains that Onchain Custodian offers will help us manage our investments”.

During its launch event, Onchain Custodian also announced important partnerships with channel partners such as Infinito who will help promote ONC’s services, but also industry groups. Alexandre Kech, CEO ONC: “Best practices around digital asset custody are critical to the future of this industry. We are committed to work with customers but also associations like the Distributed Regtech Collaboration Platform, the Malaysia Blockchain Association or the Digital Exchange Association to build the global standard for digital asset custody.”

Additional partnerships includes Accuity, the renowned compliance platform provider that ONC will use for its KYC and AML/CFT compliance process, and Polymath, a globally known Securities Token platform which will refer Onchain Custodian as one of its custodian service providers.

Thomas Borrel, Polymath: "Reputable custodians are a critical component in the security token issuance journey, especially as institutions look for new and innovative way to generate growth. We are thrilled to partner with Onchain Custodian to provide our Asia-based Issuers with a secure and dependable custody solution."

Onchain Custodian Team
Onchain Custodian
+65 6909 9350
email us here
Visit us on social media:

Expect the unexpected…

Source: EIN Presswire